Swedish Orphan Biovitrum Ab · OMXSTO:SOBI
Swedish Orphan Biovitrum Ab — Q2 2021 Earnings Presentation
23 slides from Swedish Orphan Biovitrum Ab's earnings presentation, Jul 21, 2021
Slide 1: Q2 2021 results
Q2 2021 results 21 July, 2021
Slide 2: Forward-looking statements
Forward-looking statements In order to utilise the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum AB (publ) is providing the following cautionary statement. This presentation contains forward-looking statements with respect to
Slide 3: Presenters
Guido Oelkers | CEO Presenters Henrik Stenqvist | CFO Ravi Rao | Head of R&D and CMO 3
Slide 4: Back to double-digit revenue growth – highlights in Q2
Back to double-digit revenue growth – highlights in Q2 • Solid double-digit topline growth in Q2 driven by key products - Doptelet® growth, 42 per cent at CER - Kineret® growth, 14 per cent at CER - Gamifant® growth, 46 per cent at CER • Continued patient growth - Patient growth: - 3 per cent for El
Slide 5: Q2 confirms ongoing transformation and delivery of the strategy
Q2 confirms ongoing transformation and delivery of the strategy Portfolio 2. Deliver on our late-stage pipeline and launch Grow the core (60-70% of growth) • 12 late-stage programs • Haematology is back to growth 2. Deliver on our late-stage • Develop Gamifant beyond pHLH Doptelet key growth driver
Slide 6: Haematology
Haematology 6
Slide 7: Haematology – market conditions improving
Haematology – market conditions improving Revenue (SEK M) 2 800 • Q2 revenue of SEK 2,125 M (2,037) 2 400 - Sales growth of 12 per cent at CER 2 000 • Elocta and Alprolix strengthened position with continued patient gains 1 600 - Continued impact from COVID-19 1 200 - Early indications of increased
Slide 8: Elocta sales bridge
Elocta sales bridge SEK M at CER -3% vs Q2 2020 -5.1% +4.3% -7.8% -8.7% +15.1% -1.2% 1 040 53 1 005 45 81 12 157 90 Q2 2020 FX effect Net Patient gain Consumption Price and mix Stocking effects* Other Q2 2021 per patient * Driven mainly by de-stocking in Q2 2020, 154 MSEK, following stocking in Q1 2
Slide 9: Alprolix sales bridge
Alprolix sales bridge SEK M at CER +21% vs Q2 2020 -6.3% +16.6% +11.5% -13.9% +13.6% -0.9% 438 3 42 50 49 363 60 23 Q2 2020 FX effect Net Patient gain Consumption Price and mix Stocking effects* Other Q2 2021 per patient * Driven mainly by de-stocking in Q2 2020, 38 MSEK, following stocking in Q1 20
Slide 10: Doptelet – strong growth in US and China
Doptelet – strong growth in US and China Sales (SEK M) 250 • Q2 sales of SEK 230 M (186, including milestone of 87) 200 - Sales growth of 167 per cent at CER excluding milestone 150 • US: Accelerated patient growth in Q2 vs. Q1 - COVID-19 decline improved access to healthcare 100 providers (HCPs) •
Slide 11: Immunology
Immunology 11
Slide 12: Kineret – new indications driving growth
Kineret – new indications driving growth Sales (SEK M) 600 2 400 • Q2 sales of SEK 550 M (530) 500 2 000 - Sales growth of 14 per cent at CER • Strong underlying demand driven by new indications, 400 1 600 patient growth and COVID-19 300 1 200 • SAVE-MORE: Positive result for Kineret in treating 200
Slide 13: Gamifant – continued positive trend
Gamifant – continued positive trend Sales (SEK M) 300 • Q2 sales of SEK 168 M (132) 250 - Sales growth of 46 per cent at CER 200 • Growth driven by new patients – progress in patient identification process 150 • Volatility reflects patient mix – treatment time, 100 weight of patient and other factor
Slide 14: R&D
R&D 14
Slide 15: Pipeline progress Q2
Pipeline progress Q2 • Kineret (anakinra) – SAVE-MORE demonstrated positive results in management of COVID-19 pneumonia - Submitted to the EMA in July for treatment of COVID-19 in adult patients with pneumonia at risk of severe respiratory failure - Submitted to MHRA (UK) - Emergency Use Authorisati
Slide 16: Key near term catalysts for our late-stage pipeline
Key near term catalysts for our late-stage pipeline Indication Program timeline Potential next milestone Ph1 Ph2 Ph3 Registration Efanesoctocog Haemophilia A Top-line data H1 2022 (adults), H1 2023 (paed) alfa (BIVV001) Pegcetacoplan PNH Potential EU approval H2 2021 CAD Phase 3 study to be initiate
Slide 17: Financial results
Financial results 17
Slide 18: Q2 2021: Financial results
Q2 2021: Financial results Total revenue (SEK M) Q2 Q2 H1 H1 SEK M 2021 2020 Change 2021 2020 Change Specialty Care Immunology Haematology Total revenue 3,211 3,070 5% 6,872 7,709 -11% Gross profit 2,428 2,381 2% 5,363 5,979 -10% 4,639 4,581 Gross margin1 76% 78% 78% 78% 445 218 EBITA1 922 1,018 -9%
Slide 19: Net debt walk Q2 2021
Net debt walk Q2 2021 Swedish Orphan Biovitrum AB (Publ) (SobiTM) 19
Slide 20: Conclusions
Conclusions 20
Slide 21: Conclusion
Conclusion Grow the core – returned to growth, continued patient gain and strengthened market share Deliver on late-stage pipeline and launches – further investments in our late-stage pipeline and preparing the organisation for potential launches in 2021 and 2022 Go global – seize opportunities as a
Slide 22: Q&A
Q&A 22
Slide 23: Sobi is a trademark of Swedish Orphan Biovitrum AB (publ)
Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © 2020 Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com
Swedish Orphan Biovitrum AB (Sobi) — Q2 2021 Earnings Presentation on 6ix